EUVIMEDEUVIMED entdecken
Crossref

Destination Ventricular Assist Device: A Single-Centre Experience With a Newly Approved Therapy for Advanced Heart Failure

Matanyahu Rubinstein, Steven Lim, Janelle McLean, Julia Rix, Louise Fuller, Helen Shingles, Victoria Warner, Trent Hartshorne, Caitlin Cheshire, Angeline Leet, Andrew J Taylor, David C McGiffin und 8 weitere

Heart, Lung and Circulation · 2026-03

DOI: 10.1016/j.hlc.2025.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2026-03. Verfasst von Matanyahu Rubinstein und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Alfred Health, Melbourne, Vic, Australia. Hauptthemen laut MEDLINE: Heart Failure, Heart-Assist Devices, Quality of Life, Registries. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS Destination ventricular assist device (VAD) is a newly approved upfront therapy for advanced heart failure in Australia, presenting a therapeutic option for patients who are unsuitable candidates for cardiac transplantation. This study investigated the mortality and morbidity of patients who underwent VAD implantation for advanced heart failure and subsequently determined destination therapy (DT) in the Australian healthcare context. METHOD We conducted a retrospective analysis of VAD recipients at a statewide advanced heart failure centre between 2012 and 2024. Patient and VAD characteristics, right-sided heart catheter indices, quality of life, and survival outcome data were collected for analysis. RESULTS A total of 18 patients were included in the study. The median Interagency Registry for Mechanically Assisted Circulatory Support profile was 2 (interquartile range [IQR] 1.25-3). The median survival from discharge was 5.9 years (IQR 4.1-8.3). Symptoms improved at 6 months (p=0.00016), and Kansas City Heart Failure Questionnaire, EuroQol-5 Dimensions-5 Levels, and Depression in the Medically Ill screening scores improved through to 12 months (p=0.0042, 0.01 and 0.017, respectively) after implantation. The 6-minute walk distance improved from 247.7±149.8 m to 526.9±165.5 m at 12 months after implantation (p=0.003). Right-sided heart catheter indices also improved: mean pulmonary artery pressure (36.6±10.8 to 26.1±14.4 mmHg; p=0.04), pulmonary capillary wedge pressure (25.3±7.6 to 14.1±9.1 mmHg; p=0.02), and cardiac output (3.5±1.3 to 5.5±1.2 L/min; p=0.0005). The median time to confirm DT strategy was 621 days (IQR 314-916); transplant ineligibility was attributed to a range of biopsychosocial factors. CONCLUSION Destination therapy (DT) VAD for advanced heart failure is a feasible therapeutic option for transplant-ineligible patients in Australia, associated with substantial improvements in survival and quality of life. Future studies should focus on optimising remote monitoring and patient selection to further improve long-term outcomes in this complex cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHeart-Assist DevicesQuality of LifeRegistriesHumansFemaleMaleRetrospective StudiesMiddle AgedSurvival RateFollow-Up StudiesAustralia

Stichwörter der Autor:innen

Advanced heart failureDestination therapy (DT)Ventricular assist device (VAD)

Autor:innen und Institutionen

  • Department of Cardiology Alfred Health, Melbourne, Vic, Australia.
  • Department of Cardiology Alfred Health, Melbourne, Vic, Australia; Department of Cardiology St Vincent's Hospital, Melbourne, Vic, Australia.
  • Department of Cardiology Alfred Health, Melbourne, Vic, Australia; Baker Heart and Diabetes Institute, Melbourne, Vic, Australia; Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, A…
  • Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia; Department of Cardiothoracic Surgery Alfred Health, Melbourne, Vic, Australia.
  • Department of Cardiothoracic Surgery Alfred Health, Melbourne, Vic, Australia.

Zitieren

APA

Rubinstein, M., Lim, S., McLean, J., Rix, J., Fuller, L., Shingles, H., Warner, V., Hartshorne, T., Cheshire, C., Leet, A., Taylor, A. J., McGiffin, D. C., Bergin, P., Merry, C., Doi, A., Gutman, S. J., Hare, J. L., Marasco, S., Kaye, D. M., & Patel, H. C. (2026). Destination Ventricular Assist Device: A Single-Centre Experience With a Newly Approved Therapy for Advanced Heart Failure. Heart, Lung and Circulation. https://doi.org/10.1016/j.hlc.2025.10.010

Vancouver

Rubinstein M, Lim S, McLean J, Rix J, Fuller L, Shingles H, et al. Destination Ventricular Assist Device: A Single-Centre Experience With a Newly Approved Therapy for Advanced Heart Failure. Heart, Lung and Circulation. 2026. doi:10.1016/j.hlc.2025.10.010

BibTeX
@article{Rubinstein2026,
  author = {Rubinstein, Matanyahu and Lim, Steven and McLean, Janelle and Rix, Julia and Fuller, Louise and Shingles, Helen and Warner, Victoria and Hartshorne, Trent and Cheshire, Caitlin and Leet, Angeline and Taylor, Andrew J and McGiffin, David C and Bergin, Peter and Merry, Christopher and Doi, Atsuo and Gutman, Sarah J and Hare, James L and Marasco, Silvana and Kaye, David M and Patel, Hitesh C},
  title = {Destination Ventricular Assist Device: A Single-Centre Experience With a Newly Approved Therapy for Advanced Heart Failure},
  journal = {Heart, Lung and Circulation},
  year = {2026},
  doi = {10.1016/j.hlc.2025.10.010}
}
Kostenlos starten →